Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model

International Journal of Gynecological Cancer

Volumn 19, Issue 5, 2009, Pages 814-819

  Frederick, Peter J ^a   Kendrick, James E ^a   Straughn Jr , J Michael ^a   Della Manna, Debbie L ^b   Oliver, Patsy G ^b   Lin, Hui Yi ^c   Grizzle, William E ^d   Stockard, Cecil R ^d   Alvarez, Ronald D ^a   Zhou, Tong ^c   LoBuglio, Albert F ^c   Buchsbaum, Donald J ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c and Clinical Center   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Death receptor 5; Monoclonal antibody; Ovarian cancer; TRA 8; TRAIL

Indexed keywords

ADENOSINE TRIPHOSPHATE; CARBOPLATIN; CASPASE 3; DEATH RECEPTOR 5; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TRA 8; PACLITAXEL; TRA 8; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER PATIENT; CELL ASSAY; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; EX VIVO STUDY; FEMALE; HUMAN; HUMAN TISSUE; IC 50; IMMUNOHISTOCHEMISTRY; NICK END LABELING; OVARY CANCER; PRIORITY JOURNAL; TISSUE SLICE; ADENOCARCINOMA; CYSTADENOCARCINOMA; DOSE RESPONSE; ENDOMETRIUM TUMOR; ENZYME IMMUNOASSAY; IMMUNOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OVARY TUMOR; PAPILLARY CARCINOMA; PATHOLOGY; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARBOPLATIN; CARCINOMA, PAPILLARY; COMBINED MODALITY THERAPY; CYSTADENOCARCINOMA, SEROUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; INHIBITORY CONCENTRATION 50; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TREATMENT OUTCOME;

EID: 69449083646     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a2a003     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96. Epub 2008 Feb 20.
2. Stewart L, Advanced Ovarian Cancer Trialists Group. Chemotherapy for advanced ovarian cancer. Cochrane Database of Systematic Reviews 1999, Issue 1. Art. No.: CD001418. DOI: 10.1002/14651858. CD001418.
3. Markman M. New, expanded, and modified use of approved antineoplastic agents in ovarian cancer. Oncologist. 2007;12:186-190.
4. Lee JM, Bernstein A. Apoptosis, cancer and the p53 tumour suppressor gene. Cancer Metastasis Rev. 1995;14:149-161.
5. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002;2:277-288.
6. Griffith TS, Lynch DH. TRAIL: a molecule with multiple receptors and control mechanisms. Curr Opin Immunol. 1998;10:559-563.
7. Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999;5:157-163.
8. Jo M, Kim TH, Seol DW, et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factorYrelated apoptosis-inducing ligand. Nat Med. 2000;6:564-567.
9. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002;2:420-430.
10. Ichikawa K, Liu W, Zhao L, et al. Tumoricidal activity of a novel antiYhuman DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med. 2001;7:954-960.
11. Estes JM, Oliver PG, Straughn JM Jr, et al. Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. Gynecol Oncol. 2007;105:291-298. Epub 2007 Feb 15.
12. Grizzle WE. Tissue resources in the detection and evaluation of markers. In: Srivastava S, ed. Early Detection of Cancer: Molecular Markers. Futura Publishing Co., Inc.; Armonk, NY: 1997:69-76.
13. Meadows SL, Gennings C, Carter WH Jr, et al. Experimental designs for mixtures of chemicals along fixed ratio rays. Environ Health Perspect. 2002;110:979-983.
14. McGuire WP, Hoskins WJ, Brady MF, et al. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 1995;13:1589-1599.
15. Oei AL, Sweep FC, Thomas CM, et al. The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review). Int J Oncol. 2008;32:1145-1157.
16. Cuello M, Ettenberg SA, Nau MM, et al. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol. 2001;81:380-390.
17. Arts HJ, de Jong S, Hollema H, et al. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma. Gynecol Oncol. 2004;92: 794-800.
18. Oliver PG, LoBuglio AF, Zinn KR, et al. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11. Clin Cancer Res. 2008;14:2180-2189.
19. Gibson SB, Oyer R, Spalding AC, et al. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol Cell Biol. 2000;20: 205-212.
20. Saleh MN, Percent I, Wood TE, et al. A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas. J Clin Oncol. 2008;26:3537 (Abstract).